OPOMBA: Strani so na voljo v angleškem jeziku

PLIVA has a long and successful R&D track record that dates back to 1936. Its investments in R&D have grown to a decade high of USD 40 m and represent 10% of PLIVA's healthcare turnover. The strategic goal for this continued investment is to achieve a balanced portfolio for PLIVA's short, medium and long-term growth. Commitment to a unique two-fold R&D strategy: the discovery and development of new chemical entities and the development of value added generics, is further supported by PLIVA's licensing strategy.

PLIVA has focused its expertise on NCE research, and through this "Smart Discovery Strategy" globally competitive results are expected. Research activities are focusing on the early phases of discovery and development only (i.e. Phase I/II clinical trials), while for advanced stages of development and marketing, strategic partnerships will be established. PLIVA's vision in research is to develop new drugs whose production will serve unmet medical needs and will have commercial returns in line with PLIVA's growth targets.

In development, superior results will be achieved by the in-house development of new molecules, the development of final pharmaceutical Rx or OTC drug forms and the development of Fine Chemicals processes. PLIVA's Competitive Generic Strategy is based on decades of experience and expertise in new API development coupled with regular and successful FDA inspections as well as PLIVA's excellence in chemistry and the innovative improvement of existing drugs.

Our R&D strategy binds together a top quality international research team, a network of strategic partnerships with multinational and biotech companies and a broad cooperation with various international universities and institutes. These activities are further supported by an independent body that consists of leading experts in the R&D areas of interest to PLIVA - PLIVA's International Scientific Advisory Board.